Related Experiment Videos

Status of PI3K inhibition and biomarker development in cancer therapeutics

B Markman1, F Atzori1, J Pérez-García1

  • 1Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, Spain.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|August 29, 2009
PubMed

Insights

The phosphatidylinositol 3-kinase (PI3K) pathway regulates cell growth and survival. Targeting this pathway with new drugs, alongside biomarker development, offers promise for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol 3-kinase (PI3K) pathway is crucial for cellular functions like proliferation, differentiation, and survival.
  • The PTEN tumor suppressor gene negatively regulates the PI3K pathway.
  • Alterations in PI3K pathway components are implicated in tumorigenesis and drug resistance.

Purpose of the Study:

  • To review the role of the PI3K pathway in cancer.
  • To discuss the development of targeted therapies and biomarkers for the PI3K pathway.

Main Methods:

  • Literature review of preclinical and clinical research on the PI3K pathway.
  • Analysis of genetic mutations and amplifications affecting PI3K pathway components.
  • Evaluation of emerging PI3K inhibitors in clinical trials.

Main Results:

  • Significant advancements in understanding PI3K pathway complexity and interactions.
  • Development of rationally designed drugs targeting the PI3K pathway.
  • New generation of PI3K inhibitors entering early clinical trials.

Conclusions:

  • Targeting the PI3K pathway is a promising strategy in cancer therapeutics.
  • Biomarker development is essential for optimizing the use of PI3K inhibitors.
  • PI3K inhibitors are expected to expand the options for targeted cancer treatment.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...